|
[1]
|
Savarese, G., Becher, P.M., Lund, L.H., et al. (2023) Global Burden of Heart Failure: A Comprehensive and Updated Review of Epidemiology. Cardiovascular Research, 118, 3272-3287. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Obokata, M., Reddy, Y. and Borlaug, B.A. (2020) Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC: Cardiovascular Imaging, 13, 245-257. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Henning, R.J. (2020) Diagnosis and Treatment of Heart Failure with Preserved Left Ventricular Ejection Fraction. World Journal of Cardiology, 12, 7-25. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Chen, J. and Aronowitz, P. (2022) Congestive Heart Failure. Medical Clinics of North America, 106, 447-458. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Asano, R., Abshire, M., Dennison-Himmelfarb, C. and Davidson, P.M. (2019) Barriers and Facilitators to a ‘Good Death’ in Heart Failure: An Integrative Review. Collegian, 26, 651-665. [Google Scholar] [CrossRef]
|
|
[6]
|
Vainio, L.E., Szabó, Z., Lin, R., et al. (2019) Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis after Myocardial Infarction. JACC: Basic to Translational Science, 4, 83-94. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Ishii, M., Kaikita, K., Sato, K., et al. (2017) Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) after Experimental Acute Myocardial Infarction. JACC: Basic to Translational Science, 2, 655-668. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
高彩, 金连珍, 文磊, 等. 芪苈强心胶囊治疗射血分数保留慢性心力衰竭的临床研究[J]. 中西医结合心脑血管病杂志, 2019, 17(17): 2621-2623.
|
|
[9]
|
Sun, Y.L., Ruan, X.F., Li, Y.P., et al. (2019) Comparative Analysis of Clinical Effects according to Syndrome Differentiation of Qili Qiangxin Capsules on Ischemic Heart Failure: Meta-Analysis. China Journal of Chinese Materia Medica, 44, 4975-4984.
|
|
[10]
|
Han, A.B., Zhang, J., Zhao, M.J., et al. (2016) Effects of Qili Qiangxin Capsule on Lung Structural Remodeling in Heart Failure Rats after Myocardial Infarction and Its Mechanism. Chinese Journal of Integrated Traditional and Western Medicine, 36, 1329-1334.
|
|
[11]
|
刘育英, 张继红. 芪苈山萸心衰方治疗慢性心力衰竭102例[J]. 中医杂志, 2008(7): 630.
|
|
[12]
|
周晓慧, 牛成伟, 曹凯, 等. 丹皮酚通过抑制NF-κB信号通路下调高脂血清诱导的人脐静脉内皮细胞黏附分子的表达[J]. 中国病理生理杂志, 2011, 27(2): 249-253.
|
|
[13]
|
苏真真, 张新庄, 柯志鹏, 等. 银翘解毒软胶囊治疗新型冠状病毒肺炎(COVID-19)的网络药理学研究[J]. 中草药, 2020, 51(9): 2354-2360.
|
|
[14]
|
杨璐, 崔换天, 刘相国, 等. 基于网络药理学的小柴胡汤治疗新型冠状病毒肺炎(COVID-19)发热的可行性探讨[J]. 中草药, 2020, 51(7): 1761-1775.
|
|
[15]
|
秦健峰, 郝二伟, 梁跃辉, 等. 基于文献挖掘与分子对接技术的瑶药“十八钻”抗新型冠状病毒活性成分筛选[J]. 中草药, 2020, 51(8): 2024-2034.
|
|
[16]
|
郭盛, 武文星, 谢红, 等. 基于网络药理学与分子对接技术的补肺活血胶囊用于新型冠状病毒肺炎(COVID-19)恢复期治疗的分子机制研究[J]. 中草药, 2020, 51(9): 2307-2316.
|
|
[17]
|
刘侃玲, 张瑶. 达格列净早期使用对老年急性心肌梗死后心力衰竭患者急性期心功能及炎症因子的影响[J]. 中国临床研究, 2023, 36(10): 1518-1523.
|
|
[18]
|
高风, 郭丽君, 马晓昌. 心肌梗死后心力衰竭动物模型的研究进展[J]. 中西医结合心脑血管病杂志, 2023, 21(16): 2984-2988.
|
|
[19]
|
Miura, T., Araki, M., Onoue, T., et al. (2020) Transient Marked Myocardial Thickening after Reperfused Myocardial Infarction Causing Refractory Heart Failure. CASE, 4, 106-108. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
侯江红, 吴秀娟, 王一锦, 等. 芪苈强心胶囊联合硝酸甘油治疗急性左心衰竭的临床研究[J]. 现代药物与临床, 2019, 34(11): 3244-3249.
|
|
[21]
|
Wei, J.M., Zhu, J.P., Zhang, T.Y., et al. (2019) Application of Network Pharmacology to Explore the Mechanism of Yi Xin Tai Formula in Treating Heart Failure. Digital Chinese Medicine, 2, 237-256. [Google Scholar] [CrossRef]
|
|
[22]
|
Hou, T.T., Liu, G.Z., Zang, Y.X., et al. (2019) Qiliqiangxin Attenuates Atrial Structural Remodeling in Prolonged Pacing-Induced Atrial Fibrillation in Rabbits. Naunyn-Schmiedeberg’s Archives of Pharmacology, 392, 585-592. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Matsumura, N., Takahara, S., Maayah, Z.H., et al. (2018) Resveratrol Improves Cardiac Function and Exercise Performance in MI-Induced Heart Failure through the Inhibition of Cardiotoxic HETE Metabolites. Journal of Molecular and Cellular Cardiology, 125, 162-173. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Koehne, P., Willam, C., Strauss, E., et al. (2000) Lack of Hypoxic Stimulation of VEGF Secretion from Neutrophils and Platelets. American Journal of Physiology-Heart and Circulatory Physiology, 279, H817-H824. [Google Scholar] [CrossRef]
|
|
[25]
|
Mallick, R. and Ylä-Herttuala, S. (2022) Therapeutic Potential of VEGF-B in Coronary Heart Disease and Heart Failure: Dream or Vision? Cells, 11, 3045-3060. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Mauler, M., Herr, N., Schoenichen, C., et al. (2019) Platelet Serotonin Aggravates Myocardial Ischemia/Reperfusion Injury via Neutrophil Degranulation. Circulation, 139, 918-931. [Google Scholar] [CrossRef]
|
|
[27]
|
Murphy, S.P., Kakkar, R., McCarthy, C.P., et al. (2020) Inflammation in Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 75, 1324-1340. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Boulogne, M., Sadoune, M., Launay, J., et al. (2017) Inflammation versus Mechanical Stretch Biomarkers over Time in Acutely Decompensated Heart Failure with Reduced Ejection Fraction. International Journal of Cardiology, 226, 53-59. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Li, X., Zhang, Z. and Wang, H. (2017) Fusaric Acid (FA) Protects Heart Failure Induced by Isoproterenol (ISP) in Mice through Fibrosis Prevention via TGF-β1/SMADs and PI3K/AKT Signaling Pathways. Biomedicine & Pharmacotherapy, 93, 130-145. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Ghafouri-Fard, S., Khanbabapour, S.A., Hussen, B.M., et al. (2022) Interplay between PI3K/AKT Pathway and Heart Disorders. Molecular Biology Reports, 49, 9767-9781. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Qin, W., Cao, L. and Massey, I.Y. (2021) Role of PI3K/Akt Signaling Pathway in Cardiac Fibrosis. Molecular and Cellular Biochemistry, 476, 4045-4059. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Moulin, S., Thomas, A., Arnaud, C., et al. (2020) Cooperation between Hypoxia-Inducible Factor 1α and Activating Transcription Factor 4 in Sleep Apnea-Mediated Myocardial Injury. Canadian Journal of Cardiology, 36, 936-940. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Sato, T. and Takeda, N. (2023) The Roles of HIF-1α Signaling in Cardiovascular Diseases. Journal of Cardiology, 81, 202-208. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Shao, M., Guo, D., Lu, W., et al. (2020) Identification of the Active Compounds and Drug Targets of Chinese Medicine in Heart Failure Based on the PPARs-RXRα Pathway. Journal of Ethnopharmacology, 257, Article ID: 112859. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Wang, D., Tian, L., Shi, C., et al. (2020) Network Pharmacology-Based Prediction of the Active Ingredients and Mechanism of Shen Gui Capsule for Application to Coronary Heart Disease. Computers in Biology and Medicine, 122, Article ID: 103825. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Wang, J., Zhang, Y., Liu, Y., et al. (2020) Uncovering the Protective Mechanism of Huoxue Anxin Recipe against Coronary Heart Disease by Network Analysis and Experimental Validation. Biomedicine & Pharmacotherapy, 121, Article ID: 109655. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Zhang, S.Y., Li, L., Zhang, N., et al. (2020) Systematic Pharmacological Strategies to Explore the Regulatory Mechanism of Ma Xing Shi Gan Decoction on COVID-19. Digital Chinese Medicine, 3, 96-115. [Google Scholar] [CrossRef]
|